Response to peginterferon plus ribavirin and subsequent retreatment with telaprevir-based triple therapy in a patient with chronic lymphocytic leukaemia and chronic HCV genotype 1b infection

Infectious Agents and Cancer

Anton Gillessen¹  Stefan Christensen² 

[1] Herz-Jesu-Krankenhaus Klinik für Innere Medizin, Salzstrasse 58, D-48143 Münster, Germany;Infektiologische Praxisgemeinschaft, Salzstrasse 58, D-48143 Münster, Germany

关键词: SVR;    Retreatment;    Late relapse;    Telaprevir;    Peginterferon;    Chronic lymphocytic leukaemia (CLL);    Chronic hepatitis C;   

Others  :  801018
DOI  :  10.1186/1750-9378-9-10

 received in 2014-01-07, accepted in 2014-03-07,  发布年份 2014

【 摘 要 】

Background

Case-controlled studies have clearly demonstrated a link between chronic hepatitis C infection (CHC) and B cell non-Hodgkin lymphoma (NHL). To our knowledge, this is the first case report of outcome in a patient with CLL and chronic HCV infection treated with PEG-IFN/RBV and subsequent retreated with triple therapy.

Findings

We report the case of a 54-year old, caucasian woman with a history of elevated liver enzymes diagnosed with chronic lymphocytic leukaemia (CLL) detected during investigation for hepatitis C (HCV) infection. The patient showed a haematological response following initially successful anti-HCV therapy with peginterferon plus ribavirin (PEG-IFN/RBV), with normalization of leukocyte and lymphocyte counts. She subsequently showed a late virological relapse at week 24, and was successfully retreated with telaprevir-based triple therapy. Despite an increase in leucocyte and lymphocyte count compared to baseline following triple therapy, to date there is no evidence of progression of CLL and the patient remains asymptomatic.

Conclusion

Patients with CLL may experience haematological response following successful anti-HCV therapy using IFN-based regimens. Re-treatment with triple therapy including telaprevir following late virological relapse was successful, was not associated with any unexpected safety issues, and did not adversely affect CLL status.

【 授权许可】

   
2014 Christensen and Gillessen; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Bachy E, Besson C, Suarez F, Hermine O: Hepatitis C virus infection and lymphoma. Mediterr J Hematol Infect Dis 2010, 2:e2010004.
• [2]Hermine O, Lefrère F, Bronowicki JP, Mariette X, Jondeau K, Eclache-Saudreau V, Delmas B, Valensi F, Cacoub P, Brechot C, Varet B, Troussard X: Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002, 347:89-94.
• [3]Gisbert JP, García-Buey L, Pajares JM, Moreno-Otero R: Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection. Aliment Pharmacol Ther 2005, 21:653-662.
• [4]Mazzaro C, De Re V, Spina M, Dal Maso L, Festini G, Comar C, Tirelli U, Pozzato G: Pegylated-interferon plus ribavirin for HCV-positive indolent non-Hodgkin lymphomas. Br J Haematol 2009, 145:255-257.
• [5]Chen J, Florian J, Carter W, Fleischer RD, Hammerstrom TS, Jadhav PR, Zeng W, Murray J, Birnkrant D: Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013, 144:1450-1455.
• [6]Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB: An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54:1433-1444.
• [7]Sarrazin C, Berg T, Cornberg M, Dollinger M, Ferenci P, Hinrichsen H, Klinker H, Kraus M, Manns M, Mauss S, Peck-Radosavljevic M, Schmidt H, Spengler U, Wedemeyer H, Wirth S, Zeuzem S: Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C. Z Gastroenterol 2012, 50:57-72.
• [8]Totterman TH, Danersund A, Carlsson M, Nilsson K: Effects of recombinant interferon-α and -γ on B-CLL cells in serum-free medium: Expression of activation, differentiation, and CALLA antigens. Leukemia 1987, 1(9):667-679.
• [9]Tomic J, Lichty B, Spaner DE: Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia. Blood 2011, 117(9):2668-2680.
• [10]Gisbert JP, García-Buey L, Pajares JM, Moreno-Otero R: Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: systematic review and meta-analysis. Gastroenterology 2003, 125:1723-1732.
• [11]Negri E, Little D, Boiocchi M, La Vecchia C, Franceschi S: B-cell non-Hodgkin's lymphoma and hepatitis C virus infection: a systematic review. Int J Cancer 2004, 111:1-8.
• [12]Matsuo K, Kusano A, Sugumar A, Nakamura S, Tajima K, Mueller NE: Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma: a meta-analysis of epidemiological studies. Cancer Sci 2004, 95:745-752.
• [13]Hoki T, Kuroda H, Ishikawa K, Okagawa Y, Yamada M, Sakurai T, Fujii S, Maeda M, Fujita M, Nagashima K, Nojiri S, Joumen W, Kato J: Chronic hepatitis C presenting with hepatic involvement by chronic lymphocytic leukemia responding to polyethylene glycol interferon-α-2b. Gan To Kagaku Ryoho 2012, 39:1551-1554.
• [14]Montserrat E, Villamor N, URBANOISPIZUA A, Ribera JM, Lozano M, VIVESCORRONS JL, Rozman C: Treatment of early stage-b chronic lymphocytic-leukemia with alpha-2b interferon after chlorambucil reduction of the tumoral mass. Ann Hematol 1991, 63(1):15-19.
• [15]Molica S, Alberti A: Recombinant alpha-2a interferon in treatment of B-chronic lymphocytic leukemia. A preliminary report with emphasis on previously untreated patients in early stage of disease. Haematologica 1990, 75(1):75-78.
• [16]Ziegler-Heitbrock H, Schlag R, Flieger D, Thiel E: Favorable response of early stage B CLL patients to treatment with IFN-alpha 2. Blood 1989, 73(6):1426-1430.
• [17]Pearlman BL, Traub N: Sustained virological response to antiviral therapy for chronic hepatitis C virus infection: a cure ad so much more. CID 2011, 52:889-900.
• [18]Martinot-Peignoux M, Stern C, Maylin S, Ripault MP, Boyer N, Leclere L, Castelnau C, Giuily N, El Ray A, Cardoso AC, Moucari R, Asselah T, Marcellin P: Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 2010, 51:1122-1126.
• [19]Aghemo A, Rumi MG, De Nicola S, Colombo M: Twelve-week posttreatment follow-up predicts a sustained virological response to pegylated interferon and ribavirin therapy. Hepatology 2010, 52:1170-1171.